Table 3.
All participants | CN | MCI | ||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
APT-Script | APT-PCP | APT-Script | APT-PCP | APT-Script | APT-PCP | |||||||||
r s | p | r s | p | r s | p | r s | p | r s | p | r s | p | |||
CFAB (CN: n = 29; MCI: n = 17) |
CFAB-Script | Time | 0.17 | 0.26 | 0.25 | 0.10 | 0.09 | 0.63 | 0.12 | 0.52 | 0.27 | 0.29 | 0.39 | 0.13 |
Rate | −0.42 | 0.004* | −0.75 | < 0.001* | −0.29 | 0.13 | −0.67 | < 0.001* | −0.70 | 0.002* | −0.85 | < 0.001* | ||
CFAB-ATM | Time | 0.34 | 0.02* | 0.42 | 0.005* | 0.39 | 0.04 | 0.42 | 0.03 | 0.26 | 0.33 | 0.60 | 0.01* | |
Rate | −0.28 | 0.06 | −0.53 | < 0.001* | −0.33 | 0.09 | −0.42 | 0.03 | −0.21 | 0.44 | −0.68 | 0.004* | ||
ADCS ADL-PI | Participant-report (CN: n = 24; MCI: n = 14) |
0.08 | 0.62 | 0.27 | 0.11 | 0.13 | 0.56 | 0.34 | 0.11 | −0.05 | 0.86 | 0.001 | 1.00 | |
Study partner-report (CN: n = 19; MCI: n = 10) |
0.26 | 0.18 | 0.47 | 0.009* | 0.15 | 0.53 | 0.13 | 0.60 | 0.55 | 0.10 | 0.72 | 0.02 | ||
SSPP-IADL | Participant-report (CN: n = 52; MCI: n = 7) |
0.20 | 0.13 | 0.46 | < 0.001* | 0.26 | 0.06 | 0.38 | 0.005* | 0.16 | 0.73 | 0.66 | 0.16 | |
Study partner-report (CN: n = 36; MCI: n = 3) |
−0.02 | 0.93 | 0.48 | 0.002* | 0.03 | 0.85 | 0.52 | 0.001* | −0.50 | 0.67 | −1.00 | – |
Significant p values ≤ 0.05 (uncorrected) are shown in bold along with the corresponding r values
ADCS ADL-PI Alzheimer’s Disease Cooperative Study activities of daily living prevention instrument, APT Automated Phone Task, ATM automated teller machine, CFAB Czaja Functional Assessment Battery, CN clinically normal, MCI mild cognitive impairment, PCP primary care physician, SSPP-IADL Subjective Study Partner and Participant-reported instrumental activities of daily living
*p values ≤ 0.05 after false discovery rate correction for multiple comparisons